44 enrolling by invitation. 44 Phase 1, 16 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 44 | Enrolling by invitation 44 |
| Phase 2 | 16 | Enrolling by invitation 16 |
Follow Neoplasms: new trials by email Literature Review of Neoplasms trials Research Report on Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| This is a Phase I/II Interventional, Open-label Treatment Study Designed to Evaluate the Safety and Efficacy of Anti CD 19/22 CAR- T Cells Immunotherapy for Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia/Lymphoma. CD19/22 CAR-T cells - Acute Lymphobkastic Leukemia, B Cell Lymphoma | Phase 1 / Phase 2 | Enrolling by invitation | Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology | 17 | 2026-10-10 | 2026-10-16 |
| Photobiomodulation Alone Versus Photobiomodulation Combined With Topical Oral Oxygen Therapy for Radiotherapy-Induced Oral Mucositis in Head and Neck Cancer Patients: A Randomized Clinical Trial sirolase xtent laser, blue m gel - Mucositis Oral, Head & Neck Cancer | Phase 1 / Phase 2 | Enrolling by invitation | Assiut University | 46 | 2026-08-15 | 2026-10-08 |
| A Clinical Study of HY035 Cell Injection in the Treatment of CD7-positive Relapsed or Refractory Hematologic Malignancies HY035 cell injection - Acute T Cell Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory | Phase 1 | Enrolling by invitation | Institute of Hematology & Blood Diseases Hospital, China | 13 | 2026-08-15 | 2026-08-25 |
| Molecular Imaging of EpCam Expression in Breast Cancer Using [99mTc]Tc-DARPinEc1-G3C [99mTc]Tc-DARPinEc1-G3C - Primary Breast Cancer | Phase 1 | Enrolling by invitation | Tomsk National Research Medical Center of the Russian Academy of Sciences | 10 | 2026-06-22 | 2026-08-26 |
| YS247 (Neoantigen-Pulsed DC Vaccine) for Metastatic Prostate Cancer Autologous Neoantigen-Pulsed Dendritic Cell Vaccine - Metastatic Castration-Resistant Prostate Cancer Patients, Castration-Resistant Prostate Cancer (CRPC) | Phase 1 | Enrolling by invitation | Changhai Hospital | 18 | 2026-06-01 | 2026-05-13 |
| A Study of ITC-6146RO in Patients With Advanced or Metastatic Cancer Who Have Failed Standard Therapy ITC-6146RO - Metastatic Castration-resistant Prostate Cancer, Non-small Cell Lung Cancer | Phase 1 | Enrolling by invitation | IntoCell, Inc | 102 | 2026-03-24 | 2026-11-04 |
| Evaluation of the I-phase Clinical Trial of 177Lu-HX02 Injection in Patients With Advanced Malignant Solid Tumors 177Lu-HX02 injection - Soft Tissue Sarcoma, Non-small Cell Lung Cancer | Phase 1 | Enrolling by invitation | Hexin (Suzhou) Pharmaceutical Technology Co., Ltd | 12 | 2026-01-29 | 2026-11-06 |
| PET Imaging With [18F]Fluselenamyl in People With Cardiac Amyloidosis [18F]Fluselenamyl (FSA) - Cardiac Amyloidosis | Phase 1 | Enrolling by invitation | Washington University School of Medicine | 50 | 2026-01-14 | 2026-08-18 |
| Propranolol With Tislelizumab Plus GC in Neoadjuvant Bladder UC propranolol, Tislelizumab, gemcitabine - Bladder Urothelial Carcinoma, Lymph Node Metastasis | Phase 1 | Enrolling by invitation | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 12 | 2026-01-01 | 2026-04-22 |
| Intervention of Ovarian Cancer With Antigen-specific Engineered Immune Effectors OC-EIEs - Ovarian Cancer | Phase 1 / Phase 2 | Enrolling by invitation | Shenzhen Geno-Immune Medical Institute | 20 | 2025-12-01 | 2026-11-02 |
| A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4 RNDO-564, Pembrolizumab - Non Small Cell Lung Cancer, Cervical Cancer | Phase 1 | Enrolling by invitation | Rondo Therapeutics | 149 | 2025-11-17 | 2026-06-11 |
| Safety and Efficacy of Leucine-Restricted Diet in Gastric Cancer Leucine-restricted diet. - Gastric Cancer | Phase 1 | Enrolling by invitation | Qilu Hospital of Shandong University | 37 | 2025-10-01 | 2026-04-20 |
| A Phase 1B Investigator Initiated Study of Safety and Tolerability of Dexamethasone (D) in Combination With Venetoclax-based Low-Intensity Therapy (LIT) in Treatment-Naïve Acute Myeloid Leukemia (AML): DLIT-AML Dexamethasone plus Venetoclax-based Low-Intensity Therapy - AML - Acute Myeloid Leukemia | Phase 1 | Enrolling by invitation | University of Vermont | 20 | 2025-09-01 | 2025-10-06 |
| Research on NI-FAPI-04 for the Treatment of Hypoxic and Fibroblast Activation Protein Related Tumors Injection of 177Lu-NI-FAPI - Tumor | Phase 1 / Phase 2 | Enrolling by invitation | Peking Union Medical College Hospital | 20 | 2025-08-15 | 2026-09-16 |
| JS014 Combined With Toripalimab and TACE in Unresectable HCC: a Phase Ib Study JS014 Combined With Toripalimab and TACE - Hepatocellular Carcinoma (HCC) | Phase 1 | Enrolling by invitation | Xiangya Hospital of Central South University | 20 | 2025-07-10 | 2025-09-19 |
| Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade Glioma Nivolumab, Azacitidine (AZA), lumbar puncture - Glioblastoma (GBM), Diffuse Midline Glioma (DMG) | Phase 1 | Enrolling by invitation | Andrew P. Groves | 34 | 2025-06-05 | 2026-10-27 |
| XS-03 in Combination With FOLFOX or FOLFIRI and Bevacizumab for Treatment of Metastatic Colorectal Cancer Patients With RAS Mutation Drug: XS-03, Biological: Bevacizumab, Drug: FOLFOX, Drug: FOLFIRI, Drug: XS-03, Biological: Bevacizumab, Drug: FOLFOX, Drug: FOLFIRI - Colorectal Cancer, Metastatic Colorectal Cancer With RAS Mutation | Phase 1 / Phase 2 | Enrolling by invitation | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 102 | 2025-05-23 | 2026-09-25 |
| Application of VascuLens 2.0, A Mixed Reality System for Surgical Guidance During DIEP Flap Harvest vasculens and cta - Breast Cancer | Phase 1 | Enrolling by invitation | University of British Columbia | 60 | 2025-05-01 | 2026-03-10 |
| Using CICS-1 and SPM-011 and ［18F］FBPA Commissioned by CICS and Sumitomo Heavy Industries and STELLA PHARMA BNCT, ［18F］FBPA - Thoracic Solid Malignant Tumor | Phase 1 / Phase 2 | Enrolling by invitation | Stella Pharma Corporation | 30 | 2025-04-10 | 2025-11-19 |
| Assessing the Efficacy of Repeat, Monthly Treatments of Deoxycholate for NF1 Associated Cutaneous Neurofibromas (cNFs) Kybella - Neurofibromas, Cutaneous, Neurofibromatosis 1 | Phase 1 | Enrolling by invitation | Massachusetts General Hospital | 15 | 2025-04-08 | 2026-04-22 |
Showing 20 of 44. Sign in to see all of them.
Breast Neoplasms (6) · Carcinoma, Non-Small-Cell Lung (5) · Glioblastoma (3) · Leukemia, Myeloid, Acute (3) · Prostatic Neoplasms (3) · Recurrence (3) · Sarcoma (3) · Esophageal Neoplasms (2) · Esophageal Squamous Cell Carcinoma (2) · Glioma (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lymphoma, B-Cell (2) · Lymphoma, Large B-Cell, Diffuse (2) · Melanoma (2)
Neoplasms by Histologic Type (25) · Neoplasms by Site (24) · Neoplasms, Glandular and Epithelial (11) · Neoplasms, Nerve Tissue (11) · Skin Diseases (10) · Skin and Connective Tissue Diseases (10) · Neoplasms, Germ Cell and Embryonal (9) · Neuroectodermal Tumors (9) · Breast Diseases (8) · Digestive System Diseases (7) · Digestive System Neoplasms (7) · Neoplasms, Neuroepithelial (7) · Gastrointestinal Diseases (6) · Gastrointestinal Neoplasms (6)
Radiotherapy (2) · tislelizumab (2) · Azacitidine (1) · Brachytherapy (1) · Carboplatin (1) · Cisplatin (1) · Cyclophosphamide (1) · Deoxycholic Acid (1) · Dexamethasone (1) · Folfox protocol (1) · Gemcitabine (1) · JNJ-64264681 (1) · JNJ-64619178 (1) · Magnetic Resonance Imaging (1) · Mannitol (1)
Massachusetts General Hospital (2) · Abramson Cancer Center at Penn Medicine (1) · Andrew P. Groves (1) · Assiut University (1) · Beijing Bio-Targeting Therapeutics Technology Co., Ltd (1) · Brigham and Women's Hospital (1) · Changhai Hospital (1) · Hexin (Suzhou) Pharmaceutical Technology Co., Ltd (1) · Hospital das Clínicas de Ribeirão Preto (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · IntoCell, Inc (1) · Jaime Leandro Foundation for Therapeutic Cancer Vaccines (1) · Janssen Research & Development, LLC (1) · Man Hu (1) · Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology (1)
China (17) · United States (15) · Canada (3) · Spain (3) · Australia (2) · Japan (2) · South Korea (2) · Taiwan (2) · United Kingdom (2) · Belarus (1) · Belgium (1) · Brazil (1) · Denmark (1) · Egypt (1) · France (1)
Adam S Kibel, MD (1) · Adisak Wongkajornsilp, M.D., Ph.D. (1) · David Krag, MD (1) · Djordje Atanackovic, MD (1) · Elena B Hawryluk, MD, PhD (1) · Jon Gadea Quinteiro, Principal investigator (1) · Jun Guo, MD (1) · Liangrong Shi, M.D. (1) · Lisa Wray, MD (1) · Man Hu, Dr. (1) · Michael Nathenson, MD (1) · Philip Imus, MD (1) · Richard R Anderson, MD (1) · Rodrigo Jorge, MD, PhD (1)
PMID 38291578, PMID 38713298, PMID 39348711, PMID 41026583, PMID 41521299
R01CA232174 (1), R37CA282041 (1)